Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $5.0 million.

  • 4D Molecular Therapeutics' Change in Accured Expenses fell 3853.18% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 6864.15%. This contributed to the annual value of $6.5 million for FY2024, which is 9353.31% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Change in Accured Expenses stood at $5.0 million, which was down 3853.18% from $3.1 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Change in Accured Expenses high stood at $8.1 million for Q3 2024, and its period low was -$3.4 million during Q1 2023.
  • Moreover, its 5-year median value for Change in Accured Expenses was $1.1 million (2021), whereas its average is $992052.6.
  • Examining YoY changes over the last 5 years, 4D Molecular Therapeutics' Change in Accured Expenses showed a top increase of 188148.15% in 2021 and a maximum decrease of 33927.39% in 2021.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Change in Accured Expenses stood at $535000.0 in 2021, then soared by 240.75% to $1.8 million in 2022, then increased by 9.54% to $2.0 million in 2023, then crashed by 218.48% to -$2.4 million in 2024, then soared by 310.57% to $5.0 million in 2025.
  • Its Change in Accured Expenses stands at $5.0 million for Q3 2025, versus $3.1 million for Q2 2025 and -$2.3 million for Q1 2025.